Dorien J. Buurman

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

Journal: PloS one

Published: July 16, 2018

Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: September 30, 2017

Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.

Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.

Journal: Digestive diseases and sciences

Published: December 13, 2016

Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.

Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 03, 2015

Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: June 21, 2015

Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.

Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.

Journal: Scandinavian journal of gastroenterology

Published: January 31, 2015

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.

Journal: Alimentary pharmacology & therapeutics

Published: October 14, 2014

ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.

ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: September 03, 2013

Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply.

Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 16, 2012

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Journal: Alimentary pharmacology & therapeutics

Published: June 28, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026